Literature DB >> 10569470

Expression of osteocalcin and its transcriptional regulators core-binding factor alpha 1 and MSX2 in osteoid-forming tumours.

S Hopyan1, N Gokgoz, R S Bell, I L Andrulis, B A Alman, J S Wunder.   

Abstract

Osteosarcoma, fibrous dysplasia, and myositis ossificans contain osteoid-producing cells that are not necessarily morphologically typical osteoblasts. Nevertheless, these pathologic cells may share differentiation steps with osteoblasts at the molecular level. Osteocalcin, a bone-specific extracellular matrix protein, is a marker of mature osteoblasts. Osteocalcin is upregulated by the transcription factor core-binding factor alpha 1, which is responsible for commitment to the osteoblastic lineage, and is downregulated by MSX2, a homeobox-containing transcription factor expressed during the early proliferative phase of osteoblast differentiation. Semiquantitative reverse transcription-polymerase chain reaction was used to compare expression levels of osteocalcin, core-binding factor alpha 1, and MSX2 in 34 osteosarcoma, five fibrous dysplasia, and five myositis ossificans specimens, as well as in seven normal cortical bone samples. Despite normal or elevated levels of core-binding factor alpha-1 expression in most specimens, osteocalcin expression was low or undetectable in most cases of osteosarcoma (25 of 34) and myositis ossificans (4 of 5). Single-strand conformation polymorphism and sequencing did not identify any mutations in the DNA-binding domain of core-binding factor alpha 1. However, a high level of MSX2 expression was demonstrated in these lesions, which may inhibit osteocalcin transcription. The presence of moderate levels of osteocalcin in fibrous dysplasia may contribute to the characteristic disconnected appearance of trabeculae in that entity because osteocalcin is a negative regulator of bone formation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10569470     DOI: 10.1002/jor.1100170503

Source DB:  PubMed          Journal:  J Orthop Res        ISSN: 0736-0266            Impact factor:   3.494


  7 in total

1.  p53 and MDM2 are involved in the regulation of osteocalcin gene expression.

Authors:  Hankui Chen; Kevin Kolman; Natalie Lanciloti; Michael Nerney; Emily Hays; Chet Robson; Nalini Chandar
Journal:  Exp Cell Res       Date:  2012-03-03       Impact factor: 3.905

2.  Podoplanin expression in adamantinoma of long bones and osteofibrous dysplasia.

Authors:  Takeshi G Kashima; Arunthati Dongre; Adrienne M Flanagan; Pancras C W Hogendoorn; Richard Taylor; Nicholas A Athanasou
Journal:  Virchows Arch       Date:  2011-04-16       Impact factor: 4.064

3.  Constitutive hedgehog signaling in chondrosarcoma up-regulates tumor cell proliferation.

Authors:  Tri Dung Tiet; Sevan Hopyan; Puviindran Nadesan; Nalan Gokgoz; Raymond Poon; Alvin C Lin; Taiqiang Yan; Irene L Andrulis; Benjamin A Alman; Jay S Wunder
Journal:  Am J Pathol       Date:  2006-01       Impact factor: 4.307

4.  Terminal osteoblast differentiation, mediated by runx2 and p27KIP1, is disrupted in osteosarcoma.

Authors:  David M Thomas; Sandra A Johnson; Natalie A Sims; Melanie K Trivett; John L Slavin; Brian P Rubin; Paul Waring; Grant A McArthur; Carl R Walkley; Andrew J Holloway; Dileepa Diyagama; Jonathon E Grim; Bruce E Clurman; David D L Bowtell; Jong-Seo Lee; Gabriel M Gutierrez; Denise M Piscopo; Shannon A Carty; Philip W Hinds
Journal:  J Cell Biol       Date:  2004-12-06       Impact factor: 10.539

5.  The impact of osteoblastic differentiation on osteosarcomagenesis in the mouse.

Authors:  T Quist; H Jin; J-F Zhu; K Smith-Fry; M R Capecchi; K B Jones
Journal:  Oncogene       Date:  2014-10-27       Impact factor: 9.867

Review 6.  Osteosarcoma: prognosis plateau warrants retinoblastoma pathway targeted therapy.

Authors:  Sarah E Ballatori; Philip W Hinds
Journal:  Signal Transduct Target Ther       Date:  2016-03-25

7.  Osteoblast differentiation and skeletal development are regulated by Mdm2-p53 signaling.

Authors:  Christopher J Lengner; Heather A Steinman; James Gagnon; Thomas W Smith; Janet E Henderson; Barbara E Kream; Gary S Stein; Jane B Lian; Stephen N Jones
Journal:  J Cell Biol       Date:  2006-03-13       Impact factor: 10.539

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.